Krystal Biotech (KRYS) Cash & Current Investments (2016 - 2026)

Krystal Biotech has disclosed Cash & Current Investments across 11 years of filings, most recently posting $823.4 million for Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $823.4 million, up 33.49% year-over-year; the trailing twelve-month figure through Mar 2026 was $823.4 million (up 33.49% YoY), and the FY2025 annual result was $827.8 million, up 38.54% from the prior year.
• Cash & Current Investments came in at $823.4 million for Q1 2026 at Krystal Biotech, down from $827.8 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $827.8 million in Q4 2025 to a low of $350.4 million in Q1 2023.
• The 5-year median for Cash & Current Investments is $559.6 million (2024), against an average of $560.0 million.
• Across the five-year window, Cash & Current Investments dropped 19.38% in 2023 and soared 53.62% in 2024, its largest moves.
• Krystal Biotech's Cash & Current Investments stood at $379.2 million in 2022, then jumped by 40.35% to $532.2 million in 2023, then advanced by 12.28% to $597.5 million in 2024, then surged by 38.54% to $827.8 million in 2025, then decreased by 0.53% to $823.4 million in 2026.
• The last three Cash & Current Investments figures came in at $823.4 million (Q1 2026), $827.8 million (Q4 2025), and $731.1 million (Q3 2025), per Business Quant data.